Canine Herpesvirus 1

Overview and Taxonomy of Canine Herpesvirus 1

Canine herpesvirus 1 (CHV-1), also referred to as canid herpesvirus 1 (CaHV-1), is an enveloped, double-stranded DNA virus that represents one of the most significant viral pathogens of domestic dogs (Canis lupus familiaris), with profound implications for neonatal survival, reproductive health, and ocular integrity in the canine population. The virus is unequivocally classified within the family Herpesviridae, subfamily Alphaherpesvirinae, and genus Varicellovirus [1, 3]. This taxonomic placement aligns CHV-1 with a group of viruses known for their rapid replication kinetics, cytolytic infection of epithelial cells, and, critically, their capacity to establish lifelong latent infections in sensory nerve ganglia, with subsequent reactivation under conditions of physiological stress or immunosuppression [1, 5]. The Varicellovirus genus includes other notable veterinary and human pathogens, such as felid herpesvirus 1 (FeHV-1), bovine herpesvirus 1 (BoHV-1), equine herpesvirus 4 (EHV-4), suid herpesvirus 1 (pseudorabies virus, PRV), and human herpesvirus 3 (varicella-zoster virus) [1, 3, 26]. While CHV-1 is not considered a zoonotic agent, its impact on canine health is substantial, and the World Organisation for Animal Health (WOAH) recognizes the importance of monitoring such pathogens in breeding populations to prevent significant economic losses associated with reproductive failure and puppy mortality.

Genetic and Genomic Characteristics

The CHV-1 genome is a linear, double-stranded DNA molecule, approximately 125–130 kilobase pairs in length, encoding at least 80 distinct genes. Comparative genomic analyses have been limited; until recently, only four studies had undertaken whole-genome sequencing of CHV-1 strains [3]. However, recent efforts, including the work of Rocchigiani et al. (2024) on isolates from deceased French Bulldog puppies in Sardinia, Italy, have significantly expanded our understanding of the viral genome. These Italian isolates (derived from kidney and spleen tissues of 20-day-old puppies) were found to be greater than 99% identical at the nucleotide level, clustering closely with previously sequenced strains ELAL-1 (MW353125) and BTU-1 (KX828242). This clustering reinforces the existence of a distinct clade within the CHV-1 phylogenetic tree, as initially described by Lewin et al. in 2020 [3]. The genomic conservation observed between geographically distinct strains, such as those from Italy, the United Kingdom, and the United States, suggests a relatively stable genome with limited genetic drift, though subtle variations do exist. For instance, early molecular studies on CHV-1 isolates from France (1996) and Australia (2002) demonstrated that the French isolate grouped on a separate phylogenetic branch, indicating the circulation of at least two distinct strains within Europe alone [6]. Furthermore, molecular characterization by nested PCR and phylogenetic analysis targeting the viral enzyme thymidine kinase has confirmed the presence of unique strains in the Amazon region of northern Brazil, revealing 64% to 100% nucleotide identity with sequences from Australia, Brazil, the United Kingdom, and the United States [6]. This level of genetic variability, particularly in non-coding regions or genes under selective pressure, may have implications for vaccine development and diagnostic assay design.

Virion Structure and Entry Mechanisms

Structurally, CHV-1 is a typical alphaherpesvirus. The virion consists of an icosahedral capsid containing the DNA genome, surrounded by a proteinaceous tegument layer and an outer lipid envelope studded with viral glycoproteins. The glycoproteins, particularly gB, gC, gD, and gH/gL, mediate critical steps in the viral life cycle, including attachment to host cell receptors, membrane fusion, and cell-to-cell spread. The glycoprotein B (gB) is a major target for diagnostic real-time PCR assays due to its conserved nature across CHV-1 strains [4, 21]. Early events in infection have been characterized using permissive Madin-Darby canine kidney (MDCK) cells. Studies by Nakamichi et al. (2000) demonstrated that CHV-1 attachment to permissive cells involves at least two mechanisms: a heparin-sensitive interaction mediated by heparan sulfate (HS) on the cell surface, and a second, HS-independent mechanism involving an unidentified viral component and a specific cellular receptor [13]. In non-permissive cells, the HS-dependent attachment is present, but the second mechanism is absent, leading to a severe defect in viral penetration; only 4–10% of attached CHV-1 successfully entered non-permissive cells, compared to approximately 80% in permissive MDCK cells [13]. More recent work by Eisa et al. (2021) elucidated the entry pathway into MDCK epithelial cells, revealing that CHV-1 utilizes a macropinocytosis-like, pH-independent mechanism [16]. This process is characterized by extensive host cell membrane lamellipodial ruffling and rapid internalization of virions into large, uncoated vacuoles. The entry is dependent on Na+/H+ exchangers, F-actin, myosin light-chain kinase, protein kinase C, p21-activated kinase, phosphatidylinositol-3-kinase, and focal adhesion kinase, and is independent of clathrin, caveolin, microtubules, and endosomal acidification [16]. Importantly, CHV-1 preferentially infects polarized MDCK cells from the basolateral surface, consistent with the pathobiology of a varicellovirus that targets epithelial tissues in vivo [15]. This basolateral preference may explain the virus's ability to breach mucosal barriers and establish systemic infection in neonates.

Host Range and Cell Tropism

CHV-1 exhibits a remarkably narrow host cell range in vitro, being largely restricted to cells of canine origin [25]. Among continuous cell lines, MDCK cells are the most permissive, supporting robust viral replication and producing characteristic cytopathic effects (CPE), including cell rounding, detachment, and syncytia formation. Other cell lines, such as Vero (African green monkey kidney), Hep-2 (human laryngeal carcinoma), and RD (human rhabdomyosarcoma), are non-permissive, with viral entry blocked at the penetration stage [13]. This restricted tropism is a hallmark of the virus and poses challenges for diagnostic viral isolation. In vivo, CHV-1 infects a wide array of canine tissues, including the respiratory epithelium, conjunctiva, cornea, genital mucosa, placenta, and, in neonates, virtually all visceral organs. The virus's ability to replicate at relatively low temperatures (33–35°C) in the superficial epithelium of the upper respiratory tract and genitalia is a key feature that facilitates its transmission. The virus is not known to infect humans, and the World Health Organization (WHO) does not classify CHV-1 as a zoonotic pathogen. However, its antigenic relationship with other varicelloviruses, such as FeHV-1 and phocine herpesvirus 1, has been documented [19].

Prevalence and Global Distribution

The epidemiological landscape of CHV-1 is characterized by its widespread, enzootic nature in global canine populations, with seroprevalence rates varying dramatically based on geographic region, population density, management practices, and diagnostic methodology. Early serological surveys in Norway demonstrated an exceptionally high seroprevalence of 85.5% among breeding bitches, with 38.8% displaying weakly positive titers (≥80), 44.8% moderately positive (160–320), and 16.4% strongly positive (≥640) [11]. Similarly, a study in Piedmont, Northwest Italy, reported an overall seroprevalence of 50.3% across 370 breeding dogs from 33 kennels, with negative animals identified in only ten kennels, highlighting the highly endemic nature of the virus in breeding facilities [7]. In Iran, serological surveys using indirect immunofluorescence antibody (IFA) assays estimated a seroprevalence of 20.7% among dogs in Kerman city, with significantly higher infection rates in dogs older than three years [14]. Molecular detection using real-time PCR targeting the gB gene has refined these estimates, revealing active viral shedding in 33.3% of vaginal swab samples from bitches in Iranian breeding kennels and farms [4, 9]. Elsewhere, molecular detection in the Eastern Brazilian Amazon identified CHV-1 DNA in 8.2% of dogs, while a study in Bangkok, Thailand, detected CaHV-1 in 32% of dogs with respiratory distress [18]. Conversely, some studies have reported zero prevalence; for example, a comprehensive biomolecular survey in a high-density breeding kennel in Central Italy failed to detect viral DNA by nested PCR [10], and a study of 130 male dogs in Poland detected no CHV-1 by real-time PCR [17]. These discrepancies underscore the importance of sampling methodology, population dynamics, and the intermittent nature of viral shedding. The virus is believed to have a truly global distribution, with confirmed presence across Europe, Asia, the Middle East, the Americas, and Oceania [1, 6, 24].

Clinical Syndromes and Pathobiology

The clinical spectrum of CHV-1 infection is remarkably broad, ranging from subclinical or mild upper respiratory signs in immunocompetent adults to a fulminant, fatal hemorrhagic disease in neonates. In adult dogs, the most commonly recognized manifestations are ocular and reproductive. Ocular disease, as detailed in a case report from Japan, can present as dendritic corneal ulcers, conjunctivitis, blepharitis, and less commonly, corneal hypoesthesia and quantitative tear deficiency (keratoconjunctivitis sicca) [2]. These ocular lesions arise from the virus's direct cytolytic effect on corneal and conjunctival epithelial cells. The reproductive consequences in bitches include submucosal vascular congestion, hemorrhage, fetal expulsion, abortion, stillbirth, and the birth of weak, premature pups that succumb within the first few weeks of life [1]. In males, the infection may manifest as lesions on the base of the penis and prepuce, although its impact on semen quality remains an area of active investigation [17]. CHV-1 is also a recognized component of the canine infectious respiratory disease complex (CIRDC), most often presenting as a mild, self-limiting nasal discharge, but capable of causing fatal necro-hemorrhagic pneumonia in young puppies [18]. The virus is frequently detected as a co-infection with other CIRDC pathogens, including canine adenovirus type 2, canine parainfluenza virus, Bordetella bronchiseptica, and Mycoplasma cynos [20, 22, 23, 27]. Neonatal infection is the most devastating aspect of CHV-1. Puppies infected transplacentally, or during passage through the birth canal, develop a systemic infection characterized by multifocal necrotic and hemorrhagic lesions in the liver, kidneys, lungs, spleen, and gastrointestinal tract. The absence of thermoregulatory ability in neonates (often maintained at maternal body temperature) is a pivotal factor; the virus replicates optimally at lower temperatures, enabling rapid dissemination before the immune system can mount an effective response. This highlights why aggressive warming of affected puppies does not alter disease progression [1].

Diagnostic Approaches

The gold standard for ante-mortem diagnosis of CHV-1 infection is real-time PCR, which offers high sensitivity and specificity for detecting viral DNA in conjunctival swabs, nasal swabs, oropharyngeal swabs, vaginal swabs, reproductive tissues, and pleural effusions [1, 2, 18]. Multiple TaqMan-based real-time PCR assays have been developed, targeting conserved regions of the gB or thymidine kinase genes, with detection limits as low as 10–100 DNA copies per reaction [21, 27]. These quantitative assays not only confirm infection but also allow monitoring of viral shedding dynamics and response to antiviral therapy [8, 21]. Serological methods, including serum neutralization (SN), indirect immunofluorescence assay (IFA), and immunoblotting using recombinant glycoprotein D, remain valuable for epidemiological surveys and determining population-level immunity [7, 12, 14]. However, seroconversion is not always robust or durable, and the presence of antibodies from natural infection or vaccination does not preclude the establishment of latency or the possibility of future reactivation [7, 11].

Latency and Reactivation

A defining biological feature of CHV-1, consistent with its classification within the Alphaherpesvirinae, is its capacity to establish lifelong latent infections in sensory neurons, particularly within the trigeminal ganglia. Following primary infection, the virus enters a quiescent state where the viral genome persists as an episome, with limited expression of viral genes (primarily the latency-associated transcript, LAT). Reactivation from latency can be triggered by a variety of stressors, including parturition, immunosuppression, transport, overcrowding, or administration of corticosteroids [1, 5]. Remarkably, studies utilizing intensive ocular sampling (three times daily for 28 days) in experimentally infected beagles failed to detect spontaneous subclinical ocular shedding, a finding that challenges earlier assumptions based on closely related alphaherpesviruses like HSV-1 or BoHV-1 [5]. This suggests that CHV-1 reactivation may be less frequent or of shorter duration in the ocular compartment compared to other alphaherpesviruses, though reactivation in the genital or respiratory tract may follow different dynamics. This nuanced understanding of latency has direct implications for biosecurity protocols in breeding kennels, as asymptomatic shedders can serve as unrecognized sources of infection for susceptible animals, especially pregnant bitches and neonates [1, 4].

Phylogenetic and Evolutionary Considerations

Recent whole-genome sequencing coupled with high-resolution phylogenetic analysis has begun to illuminate the evolutionary history of CHV-1. The two Italian strains isolated by Rocchigiani et al. (2024) clustered firmly within the same clade as ELAL-1 and BTU-1, suggesting a common ancestor that predates the emergence of these distinct geographic variants [3]. Conversely, analysis of CHV-1 strains from northern Brazil identified a unique cytosine insertion in the thymidine kinase gene of local isolates, providing molecular evidence for at least two distinct lineages circulating in that country: one represented by the Brazilian BTU-1 strain and another by the Pará isolates [6]. The observed 100% identity among study sequences from the Amazon region, combined with their 64–100% identity to strains from other continents, indicates that local viral evolution is occurring, possibly driven by founder effects in isolated populations [6]. This emerging picture of strain diversity underscores the need for continued genomic surveillance, particularly as global movement of dogs for breeding and competition accelerates. Such data will be critical for assessing the durability of diagnostic tools and the potential efficacy of any future vaccines. The taxonomic identity of CHV-1 thus serves not merely as a static label but as a dynamic framework for understanding its biology, epidemiology, and the ever-present risk of emergence of new variants with altered virulence or tissue tropism.

Molecular Pathogenesis and Latency of Canine Herpesvirus 1

The molecular pathogenesis of Canine Herpesvirus 1 (CHV-1) is a complex, multi-stage process that begins with viral entry into susceptible host cells and culminates in the establishment of lifelong latency, punctuated by episodes of reactivation. As a member of the genus Varicellovirus within the subfamily Alphaherpesvirinae and family Herpesviridae [1], CHV-1 shares fundamental biological properties with other alphaherpesviruses, including a relatively short replicative cycle, rapid cytopathic effect, and the capacity to establish latent infections in sensory ganglia. However, CHV-1 exhibits several unique molecular characteristics that distinguish its pathogenesis, particularly concerning its narrow host cell tropism, its distinctive entry mechanisms, and the enigmatic nature of its latent state and reactivation patterns. Understanding these molecular events is critical for comprehending the clinical manifestations of CHV-1 infection, from neonatal fatality to recurrent ocular disease and reproductive failure, and for developing targeted therapeutic and prophylactic strategies.

Viral Entry and Cellular Tropism: A Molecular Gatekeeper

The initial step in CHV-1 pathogenesis is the attachment and penetration of the virion into susceptible host cells. This process is governed by interactions between viral envelope glycoproteins and host cell surface receptors, which ultimately dictate the virus’s relatively narrow host range. Unlike many other alphaherpesviruses that can infect a wide variety of cell types across species, CHV-1 replication is largely restricted to cells of canine origin [25]. Early investigations into this phenomenon revealed that the restriction is not at the level of viral attachment. Quantitative competitive PCR studies demonstrated that CHV-1 can attach to both permissive (Madin-Darby canine kidney; MDCK) and non-permissive cell lines with comparable efficiency [13]. The critical barrier to infection in non-permissive cells lies downstream of attachment, specifically at the stage of viral penetration. While approximately 80% of attached CHV-1 virions successfully penetrate permissive MDCK cells, only 4–10% penetrate non-permissive cells [13].

This differential penetration is explained by a dual-receptor attachment model. CHV-1, like many herpesviruses, initially binds to heparan sulfate (HS) moieties on the cell surface. This interaction is necessary but not sufficient for productive entry. A second, unidentified viral component must engage a specific cellular receptor that is present only on permissive cells. The absence of this receptor on non-permissive cells renders them resistant to infection, even though the initial HS-mediated attachment occurs [13]. The identity of this critical cellular receptor for CHV-1 remains an active area of investigation, but its existence is a fundamental determinant of the virus’s tropism for canine epithelial and mucosal tissues.

Once attached to a permissive cell, CHV-1 employs a sophisticated and non-canonical entry pathway. Detailed mechanistic studies using MDCK cells have revealed that CHV-1 entry is pH-independent and occurs via a macropinocytosis-like mechanism [16]. This process is characterized by the induction of extensive lamellipodial membrane ruffling on the host cell surface, followed by the internalization of virions into large, uncoated vacuoles. This entry mechanism is dependent on a cascade of host cell signaling pathways, including the activation of Na+/H+ exchangers, F-actin dynamics, myosin light-chain kinase, protein kinase C, p21-activated kinase, phosphatidylinositol-3-kinase, and focal adhesion kinase [16]. The involvement of integrins and receptor tyrosine kinases in signaling further underscores the complexity of the entry process. Interestingly, while CHV-1 colocalizes with the fluid-phase uptake marker dextran, infection does not enhance overall fluid uptake, suggesting a distinct, non-stimulatory form of macropinocytosis [16]. Inhibitors of clathrin-mediated endocytosis, caveolin-dependent endocytosis, microtubules, and endosomal acidification have no effect on CHV-1 entry, confirming the macropinocytosis-like pathway as the primary route [16].

The polarity of epithelial cells, which are the primary targets of CHV-1 in vivo, also influences viral entry. In polarized MDCK cell cultures, CHV-1 can infect from both the apical and basolateral surfaces, but infection from the basolateral side yields significantly higher viral titers [15]. This basolateral preference is consistent with the pathobiology of other varicelloviruses and may reflect the distribution of the specific entry receptor or the efficiency of the macropinocytic machinery on that surface. Furthermore, regardless of the side of entry, the majority of newly produced progeny virus remains cell-associated, with higher titers detected in the apical compartment [15]. This pattern of viral egress has implications for viral shedding into mucosal secretions and transmission to new hosts.

Lytic Replication and Cytopathology

Following entry and uncoating, the viral genome is transported to the nucleus where a tightly regulated cascade of gene expression occurs. The lytic cycle of CHV-1 is characterized by the rapid production of infectious progeny and the destruction of the host cell. The virus encodes a full complement of enzymes required for DNA replication, including a viral thymidine kinase, which is a common target for antiviral drugs and molecular diagnostics [6, 21]. The cytopathic effect (CPE) of CHV-1 in permissive cell lines, such as MDCK and Vero cells, is characterized by cell rounding, detachment, and the formation of syncytia [25]. In the infected host, this lytic replication leads to the characteristic pathological lesions, including multifocal necrosis and hemorrhage in target organs such as the liver, kidneys, lungs, and adrenal glands, particularly in neonatal puppies [18, 21]. In adult dogs, lytic replication in the cornea leads to dendritic ulceration, a hallmark of ocular CHV-1 infection [2]. The virus also infects the respiratory epithelium, contributing to the canine infectious respiratory disease complex (CIRDC) [18, 20, 22-24, 27, 30, 31].

The Enigmatic State of Latency

A defining feature of all alphaherpesviruses is their ability to establish lifelong latent infections in the host. Following primary infection and resolution of clinical signs, CHV-1, like its relatives, retreats to a quiescent state within sensory neurons of the trigeminal ganglia and, potentially, other sites. The molecular mechanisms governing CHV-1 latency are less well-characterized than those of human herpes simplex virus 1 (HSV-1) or bovine herpesvirus 1 (BoHV-1), but key principles are shared. During latency, the viral genome persists as an episome within the neuronal nucleus. Lytic gene expression is largely silenced, with only a specific set of latency-associated transcripts (LATs) being produced. The WOAH (World Organisation for Animal Health) recognizes CHV-1 as a significant pathogen of canids, and its ability to establish latency is a major factor in its persistence within kennel environments and breeding populations [1, 7].

A critical and intriguing aspect of CHV-1 latency is the apparent difficulty in demonstrating spontaneous subclinical viral shedding, particularly from the ocular surface. This stands in stark contrast to other alphaherpesviruses, such as HSV-1 in humans or FHV-1 in cats, where periodic asymptomatic shedding is a well-documented phenomenon. In a landmark study, dogs with experimentally induced latent CHV-1 infection were subjected to intensive monitoring, including daily ophthalmic examinations and ocular swab collection three times daily for 28 days [5]. Despite this rigorous sampling protocol, no evidence of subclinical ocular viral shedding was detected by PCR, and no recurrent ocular disease was observed. Virus-neutralizing antibody titers remained stable throughout the study [5]. This suggests that either spontaneous ocular reactivation of CHV-1 is an exceedingly rare event, or that reactivation episodes are so brief and localized that they evade detection even with frequent sampling.

This finding has profound implications for understanding CHV-1 epidemiology and transmission. It implies that the primary source of viral spread within a population is likely from acutely infected animals (e.g., puppies with fatal systemic disease or adults with primary respiratory or ocular infection) or from animals experiencing overt, clinically apparent reactivation, rather than from asymptomatic shedders. This contrasts with the epidemiological model for many other herpesviruses, where asymptomatic shedding is a major driver of transmission. The molecular basis for this restricted reactivation phenotype is unknown but may involve unique regulatory elements in the CHV-1 genome or a particularly stringent host-virus interaction within the trigeminal ganglia.

Reactivation: The Role of Stress and Immunosuppression

While spontaneous subclinical shedding may be rare, it is well-established that CHV-1 can reactivate from latency in response to exogenous stimuli, most notably stress and immunosuppression [1]. This is a critical component of the virus’s pathogenesis, as it explains the occurrence of recurrent disease in adult dogs and the vertical transmission of the virus to neonates. The administration of corticosteroids, a common experimental model for reactivation in other herpesviruses, is a potent trigger. The synthetic corticosteroid dexamethasone has been shown to reactivate latent alphaherpesvirus infections in multiple species, including HSV-1 in murine models, where it triggers viral gene expression and virus production in nasopharyngeal lymphoid tissue [26]. By analogy, stress-induced elevations in endogenous cortisol are believed to be the primary physiological trigger for CHV-1 reactivation in dogs.

The molecular pathways linking stress to viral reactivation are complex and involve the modulation of host cell transcription factors and immune responses. Stress signals can directly activate the viral immediate-early gene promoters, leading to a cascade of lytic gene expression. Simultaneously, stress-induced immunosuppression, particularly the suppression of cell-mediated immunity, removes a key barrier to viral replication. This is why management practices that reduce stress, such as minimizing overcrowding, providing adequate nutrition, and controlling environmental temperature, are recommended for controlling CHV-1 in breeding kennels [1, 4, 7, 9]. The reactivation of CHV-1 in a pregnant bitch can lead to transplacental infection, resulting in fetal death, abortion, or the birth of weak, viremic puppies that succumb to fatal hemorrhagic disease shortly after birth [1, 11, 28, 29]. In adult dogs, reactivation is associated with recurrent episodes of ocular disease, including conjunctivitis and dendritic keratitis [2, 8], and can contribute to respiratory disease [18].

Sites of Latency Beyond the Trigeminal Ganglia

While the trigeminal ganglia are considered the primary site of latency for CHV-1, emerging evidence from other alphaherpesviruses suggests that additional cellular reservoirs may exist. For instance, BoHV-1 and pseudorabies virus establish a quiescent or latent infection in tonsillar tissue [26]. Recent work with HSV-1 in a murine model has demonstrated that viral DNA can be consistently detected in nasopharyngeal lymphoid tissue (NALT), which is structurally and functionally analogous to the tonsils of other mammals [26]. In this model, specific cell types within the NALT, including dendritic cells, microfold cells, and natural killer cells, were found to harbor HSV-1 DNA, and treatment with dexamethasone triggered viral replication and shedding [26]. This raises the intriguing possibility that CHV-1 may also establish a latent or quiescent infection in oropharyngeal or nasopharyngeal lymphoid tissues, such as the tonsils. If confirmed, this would provide an additional anatomical reservoir for viral persistence and a potential source for reactivation and shedding into the respiratory and oral cavities, which could be particularly relevant for transmission within kennel environments. Further research is needed to determine if CHV-1 DNA can be detected in canine tonsillar or NALT tissues during latency and whether these sites contribute to the pathogenesis of recurrent respiratory disease.

Molecular Epidemiology and Genomic Diversity

The molecular pathogenesis of CHV-1 is also shaped by its genomic diversity. Whole-genome sequencing of CHV-1 isolates has revealed a relatively high degree of genetic conservation, but distinct clades have been identified. Phylogenetic analyses of strains from different geographical regions, including Italy, the United States, Australia, and Brazil, have shown that CHV-1 isolates can be grouped into separate clades, suggesting independent evolutionary trajectories [3, 6]. For example, the Italian isolates from a fatal outbreak in French Bulldog puppies were nearly identical (>99%) and clustered closely with the ELAL-1 and BTU-1 strains, forming a distinct clade [3]. Similarly, isolates from the Brazilian Amazon region showed 100% identity among themselves but differed from a 1996 French isolate, indicating the circulation of at least two distinct strains in Brazil [6]. These genomic variations, particularly in genes encoding envelope glycoproteins involved in immune recognition and cell entry, could influence viral virulence, transmissibility, and the efficacy of immune responses. The glycoprotein D (gD), a key target for neutralizing antibodies, has been successfully expressed as a recombinant protein for serological diagnostics, and its sequence variability across strains could impact the sensitivity of such assays [12]. Continued genomic surveillance is essential for tracking the emergence of new variants and understanding their potential impact on pathogenesis and vaccine development.

Epidemiology and Global Transmission Dynamics of Canine Herpesvirus 1

Canine herpesvirus 1 (CHV-1), a member of the genus Varicellovirus within the subfamily Alphaherpesvirinae and family Herpesviridae, represents a pathogen of significant global veterinary concern. Its epidemiology is characterized by a near-ubiquitous distribution across canine populations worldwide, yet its transmission dynamics are profoundly influenced by a complex interplay of viral latency, environmental factors, host physiology, and management practices. Understanding these dynamics is critical for developing effective control strategies, particularly in breeding kennels and high-density housing facilities where the virus can become enzootic. This section provides an exhaustive analysis of the global prevalence, transmission mechanisms, risk factors, and molecular epidemiology of CHV-1, drawing upon a comprehensive synthesis of contemporary research.

Global Seroprevalence and Molecular Detection Rates

The true global burden of CHV-1 infection is difficult to ascertain due to variations in diagnostic methodologies, sample populations, and geographic regions. However, a consistent picture emerges from serological and molecular surveys: CHV-1 is endemic in most canine populations studied, with prevalence rates ranging from low to extremely high depending on the cohort. Serological studies, which detect antibodies indicative of past or current infection, generally report higher prevalence than molecular detection of viral DNA, reflecting the lifelong persistence of the virus following initial infection.

In Europe, seroprevalence data reveal a highly variable landscape. A landmark study in Norway found that 85.5% of 193 breeding bitches were seropositive, with titers ≥80, indicating widespread exposure [11]. This high rate was observed despite the absence of vaccination, suggesting that natural infection is the primary driver of population immunity in this region. Similarly, in Northwest Italy, a study of 370 breeding dogs across 33 kennels reported an overall seroprevalence of 50.3%, with rates within individual kennels ranging from 7.1% to 100% [7]. Notably, this study found that only 8.4% of dogs had been vaccinated, reinforcing that the observed antibodies were predominantly the result of natural infection. In contrast, a study in a single high-density breeding kennel in Central Italy found no seropositive dogs and no viral DNA by nested PCR, suggesting that the virus was not circulating within that specific facility at the time of sampling [10]. This stark contrast highlights the focal nature of CHV-1 transmission, where the virus can be absent from isolated, well-managed populations while being highly prevalent in others. In the Czech Republic, an immunoblot assay using recombinant glycoprotein D detected antibodies in 33% of 100 canine sera, further confirming endemic circulation in Central Europe [12].

Molecular detection rates, which indicate active or recent viral shedding, tend to be lower but are nonetheless substantial in high-risk populations. In Iran, a series of studies using real-time PCR on vaginal swabs from breeding kennels and farms reported prevalence rates of 33.3% (21/63) [4, 9]. Another Iranian study examining reproductive tissues (uterine biopsies and vaginal swabs) from 140 dogs found a 15% positivity rate, with 20% of uterine samples and 10% of vaginal samples testing positive [28, 29]. These findings are particularly significant as they demonstrate active viral presence in the reproductive tract, a key site for venereal and vertical transmission. In the Eastern Brazilian Amazon, a pioneering study detected CHV-1 DNA in 8.2% (13/159) of dogs from four municipalities, marking the first molecular confirmation of the virus in northern Brazil [6]. In Thailand, a survey of 100 dogs with respiratory distress found a remarkably high prevalence of 32% for CHV-1 DNA in nasal and oropharyngeal swabs, with the virus frequently detected as a co-infection with other agents of the canine infectious respiratory disease complex (CIRDC) [18]. In Japan, a molecular survey of dogs with and without respiratory signs found CHV-1 to be the second most frequently detected pathogen after Bordetella bronchiseptica, particularly in kennel environments [30]. Conversely, a study in Poland using real-time PCR on preputial swabs and semen from 130 male dogs failed to detect any CHV-1 DNA, suggesting a very low or absent prevalence in that specific population [17]. Similarly, a study in New Zealand detected CHV-1 in only 4% of dogs with CIRDS and not at all in healthy controls, indicating a relatively low circulation level in that geographic region [24]. These data collectively underscore that while CHV-1 is globally distributed, its prevalence is highly heterogeneous, driven by local management practices, population density, and biosecurity measures.

Transmission Pathways and Shedding Dynamics

The transmission of CHV-1 is multifaceted, involving direct contact with infected secretions, venereal routes, and vertical transmission from dam to offspring. The virus is shed in ocular, nasal, and oropharyngeal secretions, as well as in vaginal and preputial fluids, and can be present in semen [1, 18, 28]. The primary mode of transmission among adult dogs is through direct contact with these infected secretions, which can occur during mating, sniffing, or shared use of contaminated fomites such as food bowls, bedding, and kennel surfaces.

A critical feature of CHV-1 epidemiology is its ability to establish lifelong latency in sensory ganglia and other tissues, with periodic reactivation and asymptomatic shedding. This mechanism allows the virus to persist within a population even in the absence of clinical disease, serving as a constant source of new infections. Stressors such as overcrowding, poor nutrition, concurrent illness, transport, and parturition are well-documented triggers for reactivation [1]. However, the precise patterns of subclinical shedding remain an area of active investigation. A seminal experimental study by Ledbetter et al. (2021) rigorously examined this phenomenon in laboratory beagles with experimentally induced latent ocular CHV-1 infection. Despite intensive sampling (three times daily for 28 days) and daily ophthalmic examinations, no evidence of subclinical ocular viral shedding or recurrent ocular disease was detected [5]. This finding is fundamentally distinct from many other alphaherpesviruses, such as feline herpesvirus-1 or human herpes simplex virus, which exhibit frequent spontaneous reactivation. The authors posited that ocular shedding episodes in CHV-1 may be extremely brief and rapidly cleared, or that reactivation may occur primarily at non-ocular sites, such as the genital or respiratory tract. This suggests that the oronasal and genital mucosae, rather than the ocular surface, may be the primary sites for subclinical transmission in adult dogs.

Venereal transmission is a well-established route, particularly relevant in breeding kennels. The detection of CHV-1 DNA in vaginal swabs and uterine biopsies from clinically normal bitches and those with reproductive disorders confirms that the reproductive tract is a significant reservoir [4, 9, 28]. The virus can be transmitted from an infected male to a female during mating, or vice versa. Furthermore, vertical transmission is a major cause of neonatal mortality. Puppies can become infected in utero via transplacental passage, leading to abortion, stillbirth, or the birth of weak, viremic puppies [1]. More commonly, infection occurs during passage through the birth canal or shortly after birth through contact with infected vaginal secretions or oronasal fluids from the dam [1]. The high susceptibility of neonatal puppies is due to their immature thermoregulatory system; CHV-1 replicates optimally at temperatures slightly below the normal canine body temperature, making the cooler body temperature of newborns ideal for viral proliferation [1].

Risk Factors and Population Dynamics

Numerous epidemiological studies have sought to identify risk factors associated with CHV-1 infection, with varying degrees of success. The most consistently identified risk factor is population density and housing environment. Multiple studies have demonstrated that dogs housed in breeding kennels, farms, or shelters have significantly higher prevalence rates compared to privately owned, single-dog households. In Iran, the prevalence in farm dogs (43.7%) was notably higher than in kennel dogs (29.7%) [4, 9]. In Japan, kennel-housed dogs showed a higher detection rate of CHV-1 and other respiratory pathogens compared to private household dogs [30]. This association is likely driven by the increased frequency of direct contact, shared airspace, and heightened stress levels in high-density environments, all of which facilitate viral transmission and reactivation.

Age is another factor that influences seroprevalence. Several studies have found that seropositivity increases with age, reflecting cumulative exposure over time. In Iran, dogs older than three years had a significantly higher infection rate (15.9%) compared to younger dogs (4.8%) [14]. In Italy, seropositivity was significantly lower in prepubertal bitches and animals younger than 1.5 years, but among those young seropositive animals, titers were often very high, suggesting recent, primary infection [7]. In Norway, while there was no difference in mean age between seropositive and seronegative dogs, the magnitude of antibody titers varied with season, with higher titers observed in summer and fall, indicating seasonal patterns of viral transmission [11]. This seasonal effect may be linked to increased breeding activity or environmental factors that influence viral survival or host stress.

The role of sex as a risk factor appears to be minimal, with most studies reporting no significant difference in prevalence between males and females [7, 11, 14]. Similarly, breed has not been consistently identified as a significant risk factor [4, 28]. However, a history of reproductive disorders, such as abortion, stillbirth, pyometra, or vaginitis, has been associated with CHV-1 detection in some studies. In Iran, five of the 21 positive reproductive samples came from dogs with a history of such disorders [28]. This suggests that CHV-1 may be a contributing factor to these conditions, although it is also possible that the underlying pathology or associated stress triggers viral reactivation.

Participation in dog shows, competitions, and travel has also been implicated as a risk factor. In Norway, participation in competitions and shows, along with season and previous whelping, explained 67-78% of the variation in antibody titers [11]. This is likely due to increased contact with unfamiliar dogs and exposure to novel environments, which can introduce the virus and cause stress-induced reactivation in latently infected animals. Vaccination status is a critical, albeit complex, factor. In regions where a CHV-1 vaccine is available (e.g., Europe), its use is variable. In the Italian study, vaccination was performed in only 21.2% of kennels and 8.4% of dogs, and its impact on overall seroprevalence was minimal compared to natural infection [7]. The vaccine is designed to reduce clinical disease and shedding but does not prevent infection or latency. Consequently, even in vaccinated populations, the virus can continue to circulate.

Molecular Epidemiology and Phylogenetic Insights

The molecular epidemiology of CHV-1 has been significantly advanced by whole-genome sequencing and phylogenetic analyses. These studies have revealed that CHV-1, like other herpesviruses, exhibits a relatively stable genome but with sufficient genetic diversity to delineate distinct clades and geographic lineages. Early phylogenetic studies based on partial gene sequences, such as thymidine kinase (TK) and glycoprotein B (gB), have provided initial insights. For instance, a study from the Brazilian Amazon identified two distinct CHV-1 strains circulating in Brazil, with one strain from Pará showing 100% identity to a 2002 Australian isolate, suggesting international transmission events [6].

More recently, whole-genome sequencing has provided a higher-resolution picture of CHV-1 evolution. A landmark study by Rocchigiani et al. (2024) sequenced two CHV-1 isolates from a fatal outbreak in French Bulldog puppies in Sardinia, Italy [3]. These Italian genomes were nearly identical (>99%) and clustered closely with the ELAL-1 (USA) and BTU-1 (Brazil) strains, forming a distinct clade that was previously identified by Lewin et al. (2020). This finding confirms the existence of a globally distributed clade of CHV-1 and provides evidence for the international spread of specific viral strains, likely through the movement of infected dogs. The high degree of genetic similarity between strains from different continents (Italy, USA, Brazil) suggests that CHV-1 is a relatively stable virus with a slow rate of evolution, and that its global dissemination is a recent phenomenon driven by human-mediated dog transport.

The study also highlighted the importance of whole-genome analysis for understanding viral pathogenesis. The Italian isolates were obtained from puppies that died from a severe, systemic infection, and their genomes contained specific mutations in genes associated with virulence and immune evasion. Future studies correlating genomic data with clinical outcomes will be essential for identifying molecular determinants of pathogenicity. Furthermore, the development of robust diagnostic tools, such as TaqMan-based real-time PCR assays targeting the gB gene, has enabled rapid and sensitive detection of CHV-1 DNA across a wide range of clinical samples, facilitating large-scale epidemiological surveillance [21]. These assays are now being incorporated into multiplex panels for the simultaneous detection of multiple CIRDC pathogens, providing a comprehensive view of the respiratory virome in canine populations [20, 23, 27].

Implications for Control and International Health

The epidemiological data presented here have profound implications for the control of CHV-1, particularly in breeding establishments and kennels. The high prevalence of latent infection and the potential for stress-induced reactivation mean that eradication of the virus from an endemic population is extremely challenging. Management strategies must therefore focus on reducing the risk of transmission and minimizing the impact of clinical disease. Key measures include maintaining low population density, implementing strict hygiene and quarantine protocols for new arrivals, reducing environmental stressors, and ensuring adequate nutrition. In breeding kennels, serological screening of bitches prior to mating can identify seronegative animals that are at high risk of primary infection during pregnancy. These animals should be isolated from potentially shedding dogs and, where available, vaccinated prior to breeding.

From a global health perspective, CHV-1 is not a zoonotic pathogen and poses no direct threat to human health. However, its economic impact on the canine breeding industry is substantial, resulting in significant financial losses due to neonatal mortality, infertility, and veterinary care costs [1]. The virus is also a recognized component of the CIRDC, a multifactorial syndrome that causes significant morbidity in shelter and kennel populations worldwide [18, 20, 23]. The World Organisation for Animal Health (WOAH) does not list CHV-1 as a notifiable disease, but its impact on animal welfare and the canine industry warrants continued surveillance and research. The development of more effective vaccines that can prevent latency or induce sterilizing immunity remains a critical unmet need. Until such vaccines are available, the control of CHV-1 will continue to rely on a combination of biosecurity, stress reduction, and strategic management practices tailored to the specific epidemiological context of each facility.

Clinical Manifestations: Reproductive and Ocular Disease Associated with Canine Herpesvirus 1

Canine herpesvirus 1 (CHV-1), a member of the subfamily Alphaherpesvirinae within the family Herpesviridae, is a globally distributed pathogen whose clinical significance is most profoundly felt in two distinct but interrelated domains: reproductive failure and ocular disease [1]. The clinical manifestations in these systems are not merely incidental findings; they reflect the virus’s fundamental biology, its predilection for mucosal epithelia, its capacity for immune evasion through latency, and its devastating impact on neonatal viability. Understanding the nuanced presentations of CHV-1 in the reproductive tract and the eye is critical for clinicians, as the spectrum of disease ranges from subclinical shedding, which perpetuates enzootic cycles, to acute, life-threatening illness in puppies and chronic, recurrent lesions in adults.

Reproductive Disease in Bitches and Neonates

The reproductive consequences of CHV-1 infection are among the most economically and emotionally burdensome aspects of this pathogen, particularly in breeding kennels where the virus can become enzootic [1, 4, 7]. The clinical spectrum is broad, encompassing subclinical carrier states, mild vaginitis, and severe pregnancy wastage. Central to the pathogenesis is the virus’s ability to establish lifelong latency following primary infection, with reactivation triggered by stress, immunosuppression, or parturition itself [1]. This reactivation leads to asymptomatic or mildly symptomatic viral shedding in vaginal and oronasal secretions, serving as the primary mechanism for transmission to both naive contacts and, critically, to newborn puppies during passage through the birth canal [1, 4].

Maternal Clinical Signs and Reproductive Wastage. In adult bitches, CHV-1 infection during gestation can result in a constellation of adverse outcomes that are often mistaken for other causes of infertility. These include resorption of embryos, abortion, stillbirth, and the premature delivery of live, but non-viable, puppies [1, 3, 4, 28]. The pathological basis for these outcomes is a necrotizing and hemorrhagic placentitis, often accompanied by multifocal necrosis of the fetal liver, lungs, kidneys, and spleen [3, 21]. The virus’s tropism for the highly vascularized fetal tissues leads to disseminated intravascular coagulation and severe systemic compromise in the fetus, which is incapable of mounting an effective febrile response due to its immature thermoregulatory system [1].

Importantly, the clinical signs in the bitch herself are often absent or mild. Some animals may exhibit minimal vulvar discharge or subclinical vaginitis, but many appear systemically healthy, making the diagnosis elusive without molecular investigation [1, 28]. Molecular surveys have demonstrated that CHV-1 DNA can be detected in vaginal swabs and uterine biopsies from bitches with a history of reproductive disorders, including pyometra, metritis, stillbirths, and vaginitis, even in the absence of overt clinical illness [28, 29]. For instance, Rezaei et al. (2020) in Iran detected CHV-1 DNA in 20% of uterine samples and 10% of vaginal samples from a mixed population of dogs, with a notable proportion of positive samples originating from animals with documented reproductive failure [28, 29]. This underscores the role of CHV-1 as a stealth pathogen in the breeding population, contributing to the "infertility" complex without alerting the clinician to its presence.

Neonatal Death: A Rapid and Devastating Course. The most classic and feared manifestation of CHV-1 infection is neonatal death, typically occurring within the first one to three weeks of life [1, 3, 21]. Puppies born to a seronegative bitch that is actively shedding virus at parturition are at extreme risk, as they lack protective maternally derived antibodies. The infection progresses with alarming speed, often resulting in the sudden death of an entire litter within 24 to 48 hours. Affected puppies may exhibit a brief period of distress characterized by incessant crying, abdominal pain, anorexia, and serous to hemorrhagic nasal discharge. However, the most severe cases present with acute death, with no premonitory signs [3].

Pathologically, the hallmark of neonatal CHV-1 is a multifocal necrotizing and hemorrhagic disease, particularly involving the liver, lungs, kidneys, and adrenal glands. These lesions, described as "necrotic foci with hemorrhage," are a direct result of viral cytopathology and are not always accompanied by the formation of classic intranuclear inclusion bodies, which can make histopathological diagnosis challenging [3, 18]. The high mortality rate in neonates is attributed to their inability to regulate body temperature; CHV-1 replicates optimally at cooler temperatures (33–37°C), and the inability of puppies to mount a fever allows unchecked viral replication [1]. This temperature-dependent replication is a key factor that explains the age-restricted nature of the fulminant neonatal disease, as older puppies and adults can mount a febrile response that inhibits viral replication.

Subclinical Shedding and Latency in the Male. While the reproductive disease in bitches is often associated with pregnancy failure, the role of the male as a carrier and vector cannot be overstated. CHV-1 can be shed in semen and preputial secretions, and infected males may present with lesions on the base of the penis and prepuce, which can manifest as papules, vesicles, or ulcers [17]. However, many infected males are asymptomatic, shedding the virus intermittently without any detectable clinical signs [17]. This creates a significant challenge for biosecurity in breeding kennels, as a single latently infected stud dog can perpetuate infection within a population.

Ocular Disease in Adult Dogs

The ocular manifestations of CHV-1 in mature dogs are distinct from the systemic, hemorrhagic disease seen in neonates. In adults, the eye represents a site of both primary and recurrent disease, with clinical signs ranging from mild, self-limiting conjunctivitis to severe, vision-threatening keratitis [1, 2]. The pathobiology of ocular CHV-1 is complex and is intimately linked to the virus’s ability to establish latency in the trigeminal ganglia and, potentially, in other ocular and periocular tissues [5, 26]. Reactivation from latency, triggered by stress, immunosuppression (including corticosteroid administration), or concurrent illness, results in virus shedding into the conjunctival sac and the cornea, leading to clinical disease [1, 5].

Spectrum of Ocular Lesions. The presenting signs of ocular CHV-1 are highly variable. On the milder end, animals may develop blepharitis (inflammation of the eyelids) and conjunctivitis, characterized by chemosis, hyperemia, and a serous or mucoid ocular discharge [1]. These signs are non-specific and can easily be mistaken for allergic conjunctivitis, bacterial infection, or trauma. However, CHV-1 has a distinct predilection for the corneal epithelium, where it induces a characteristic cytopathic effect.

The most pathognomonic corneal lesion associated with CHV-1 is the dendritic ulcer, a branching, linear epithelial defect that can be visualized with fluorescein staining. This lesion is the ocular equivalent of the classic herpetic skin vesicle and reflects the virus’s ability to spread from cell to cell, causing a characteristic arborizing pattern of epithelial cell death [1, 2]. Usami et al. (2025) documented a classic case in a 5-year-old French Bulldog in Japan, where the presence of a dendritic corneal ulcer, alongside quantitative tear deficiency (keratoconjunctivitis sicca, KCS) and corneal hypoesthesia, was the key diagnostic clue [2]. In addition to dendritic ulcers, CHV-1 can also cause non-ulcerative keratitis, manifesting as a geographic or disciform keratitis, and chronic stromal keratitis, which can lead to corneal scarring, edema, and neovascularization [1].

Corneal Hypoesthesia and Quantitative Tear Deficiency. A critical clinical finding that is increasingly recognized in cases of ocular CHV-1 is the association with reduced corneal sensitivity and decreased tear production [2]. The corneal hypoesthesia is believed to result from viral damage to the sensory nerve endings within the corneal stroma, a consequence of the virus traveling along the trigeminal nerve from the site of primary infection. Loss of corneal sensation can create a neurotrophic keratopathy, a vicious cycle where the damaged cornea becomes even more susceptible to injury and delayed healing. Similarly, the reduced tear production (quantitative tear deficiency or KCS) may be due to viral involvement of the lacrimal gland or its innervation [2]. This combination of dendritic ulceration, KCS, and corneal anesthesia creates a clinical triad that, while not present in every case, should strongly raise suspicion for herpetic ocular disease.

Subclinical Shedding and the Challenge of Latency. A perplexing aspect of ocular CHV-1 is the difficulty in detecting spontaneous subclinical viral shedding from the eyes of latently infected dogs. Ledbetter et al. (2021) conducted an intensive study in laboratory beagles with experimentally induced latent infection, collecting ocular swabs three times daily over a 28-day period. Despite this intensive sampling protocol, no CHV-1 DNA was detected by PCR, and no clinical signs of ocular disease were observed [5]. This finding stands in contrast to closely related alphaherpesviruses (like human herpes simplex virus or feline herpesvirus-1), which exhibit frequent episodes of spontaneous shedding. This suggests that the mechanisms governing reactivation and shedding of CHV-1 from the eye are particularly stringent or that the reactivation events, when they occur, are so brief and cleared so rapidly that they fall below the detection limit of even highly frequent sampling [5]. This biological characteristic complicates the interpretation of a single negative PCR result from an ocular swab, as it does not rule out the presence of a latent infection that could reactivate under appropriate stress.

Role in Canine Infectious Respiratory Disease Complex (CIRDC). It is essential to note that ocular disease rarely occurs in isolation. CHV-1 is a recognized component of the canine infectious respiratory disease complex (CIRDC), and its ocular manifestations frequently accompany mild to moderate respiratory signs, particularly in juvenile and young adult dogs [18, 20, 23]. In fact, studies screening dogs for CIRDC have detected CHV-1 in a significant proportion of animals, often as a co-infection with other pathogens such as Bordetella bronchiseptica, canine parainfluenza virus, and canine adenovirus type 2 [18, 20, 30]. The ocular signs (conjunctivitis, keratitis) in this context are thus part of a broader syndrome of mucosal inflammation and are not pathognomonic for ocular herpetic disease alone.

Diagnostic and Clinical Implications

The diagnosis of CHV-1 associated reproductive and ocular disease relies heavily on molecular detection of viral DNA, particularly via real-time PCR (qPCR) assays targeting the glycoprotein B (gB) gene [21, 23, 27]. PCR is highly sensitive and specific, allowing for the detection of virus during active shedding, even in subclinical carriers, and it is the current gold standard for confirming clinical suspicion. Serology (virus neutralization) can be useful for epidemiological studies and for identifying seronegative bitches at risk during pregnancy, but a single serological test cannot distinguish between past infection and active disease [7, 11, 14]. In ocular cases, the characteristic dendritic keratitis, if present, is a highly suggestive clinical sign, but PCR confirmation is recommended to differentiate CHV-1 from other causes of corneal ulceration (trauma, bacterial infection, foreign body) and to guide specific antiviral therapy [2].

Management of these conditions requires a two-pronged approach: specific antiviral therapy for active disease and management strategies to limit transmission, particularly in breeding environments. Topical antiviral agents, such as 0.15% ganciclovir gel or 0.1% idoxuridine solution, have been shown to be effective in treating ocular CHV-1. Ledbetter et al. (2018) demonstrated that topical ganciclovir significantly reduced clinical disease scores, inflammation, and the duration of viral shedding in experimentally infected dogs [8]. Usami et al. (2025) reported successful resolution of dendritic ulcers, improvement of corneal sensitivity, and normalization of tear production in a dog treated with idoxuridine [2]. While prophylactic topical antimicrobial therapy is recommended to prevent secondary bacterial infection in ulcerative keratitis, it is critical to recognize that elevating the environmental temperature for affected puppies, a historically recommended intervention, has been shown to be ineffective in modifying the course of neonatal disease [1].

The identification of latently infected carriers remains the most significant clinical challenge. Due to the intermittent and often subclinical nature of viral shedding, particularly from the reproductive tract and the eye, eliminating CHV-1 from a kennel is extraordinarily difficult. Strict biosecurity, quarantine of incoming animals, and strategic culling of known shedders can help, but the virus’s ability to remain hidden in neural ganglia ensures that complete eradication is rarely achievable in high-density populations [4, 10]. For breeding animals, the goal shifts from elimination to management: keeping bitches seropositive (through natural exposure or vaccination where available) to ensure that maternally derived antibodies protect the critical first weeks of life, and minimizing stress that could trigger reactivation during gestation [7].

Diagnostic Approaches: Molecular Detection and Serological Assays for Canine Herpesvirus 1

The accurate and timely diagnosis of Canine Herpesvirus 1 (CHV-1) infection is paramount for effective clinical management, epidemiological surveillance, and the implementation of control strategies, particularly in breeding kennels where the virus can cause devastating reproductive losses and neonatal mortality. The diagnostic landscape for CHV-1 is dichotomous, comprising direct detection methods that identify viral nucleic acid or antigen, and indirect serological assays that measure the host's humoral immune response. Each modality possesses distinct advantages, limitations, and specific applications, ranging from the confirmation of acute clinical disease to the assessment of population-level seroprevalence and latent infection status. The selection of an appropriate diagnostic approach is critically dependent on the clinical context, the stage of infection, the sample type, and the specific objective of the testing protocol, whether for individual case management or large-scale epidemiological investigation.

Molecular Detection: Polymerase Chain Reaction (PCR) and Advanced Nucleic Acid-Based Techniques

The advent of molecular diagnostics has revolutionized the detection of CHV-1, with polymerase chain reaction (PCR)-based assays now regarded as the gold standard for direct viral detection [1, 4, 28]. PCR offers unparalleled sensitivity and specificity, enabling the identification of minute quantities of viral DNA even in subclinical infections or from samples with low viral loads. This is particularly critical for CHV-1, which establishes lifelong latency and can reactivate intermittently without overt clinical signs, making viral isolation via cell culture exceedingly difficult. The widespread adoption of PCR is attributed to its rapid turnaround time, robustness, and the capacity to process a diverse array of clinical specimens, including vaginal, preputial, nasal, oropharyngeal, and conjunctival swabs, as well as tissue samples from necropsy cases such as kidney, spleen, liver, and lung [3, 21].

Conventional and Real-Time PCR Assays

Conventional gel-based PCR assays, often targeting conserved genes such as those encoding thymidine kinase (TK) or glycoprotein B (gB), have been instrumental in initial molecular epidemiological studies [6, 21]. These assays, while effective for qualitative detection, are being progressively supplanted by real-time or quantitative PCR (qPCR). Real-time PCR offers the significant advantage of simultaneous detection and quantification of viral DNA, providing invaluable data on viral load. This quantitative capacity is crucial for monitoring the kinetics of viral shedding during acute infection, assessing the efficacy of antiviral therapies, and differentiating between active viral replication and residual nucleic acid from a resolved infection [2, 8, 21]. For instance, in a case of ocular CHV-1 in a French Bulldog, quantitative PCR was successfully employed to demonstrate a reduction in viral shedding from conjunctival swabs following the initiation of topical idoxuridine therapy, directly correlating molecular findings with clinical improvement [2]. Similarly, experimental studies using ganciclovir ophthalmic gel demonstrated significantly reduced viral shedding duration (0.4 days in the treatment group versus 6.2 days in controls), as measured by PCR, underscoring the assay's utility in antiviral drug evaluation [8].

TaqMan-based real-time PCR assays, targeting the highly conserved glycoprotein B gene, have demonstrated exceptional analytical performance. Decaro et al. [21] developed and validated a TaqMan assay with a detection limit of 10¹ DNA copies per 10 µL of template for standard DNA, exhibiting a 1-log higher sensitivity compared to a conventional gel-based TK gene PCR. This assay showed no cross-reactivity with other common canine DNA viruses, including canine parvovirus type 2, canine minute virus, or canine adenovirus types 1 and 2, confirming its high specificity [21]. The adaptability of real-time PCR for high-throughput screening has made it indispensable for large-scale prevalence studies. Molecular surveys in Iran, utilizing real-time PCR targeting the gB gene, have reported CHV-1 prevalence rates of 15.0% in reproductive specimens from adult dogs and 33.3% in vaginal samples from breeding kennels and farms, emphasizing the virus's significant circulation in these environments [4, 9, 28]. The detection of viral DNA in 20% of uterine biopsies underscores the potential for CHV-1 to cause subclinical reproductive tract infections that may contribute to infertility without obvious clinical signs [28].

Multiplex PCR Panels for Canine Infectious Respiratory Disease Complex (CIRDC)

CHV-1 is a recognized component of the canine infectious respiratory disease complex (CIRDC), a multifactorial syndrome where coinfections are common [18, 20, 31]. Consequently, there has been a substantial push toward the development of multiplex PCR panels that can simultaneously detect multiple respiratory pathogens from a single sample. These panels are invaluable for differential diagnosis, as the clinical signs of CHV-1-associated respiratory disease, mild nasal discharge, coughing, are indistinguishable from those caused by canine adenovirus type 2 (CAdV-2), canine parainfluenza virus (CPIV), canine distemper virus (CDV), Bordetella bronchiseptica, and Mycoplasma species [20, 23].

One of the most comprehensive panels to date, developed by Thieulent et al. [20], comprises four one-step multiplex qPCR/RT-qPCR assays capable of detecting twelve CIRDC-associated pathogens, including CHV-1, SARS-CoV-2, and three distinct canine influenza virus subtypes. This panel demonstrated high specificity and analytical sensitivity, and in clinical testing of 76 CIRDC-suspected dogs, it identified CHV-1 alongside Mycoplasma canis and Mycoplasma cynos as frequently detected agents, with coinfections identified in 30.3% of samples [20]. Similarly, a triplex real-time PCR method has been specifically optimized for the simultaneous detection of CHV-1, CAdV-2, and CDV, achieving limits of detection of 10² copies/µL for CHV-1 and 10¹ copies/µL for the other two viruses [27]. This multiplex approach was validated against 122 clinical samples and demonstrated superior sensitivity and reliability compared to conventional singleplex PCR, highlighting the practical benefits of reducing time, cost, and sample volume while maximizing diagnostic yield [27]. The development of such panels aligns with the recognition that CHV-1 frequently participates in polymicrobial infections, with studies showing that as many as 68.8% of CHV-1-positive dogs in a respiratory disease cohort were co-infected with other CIRDC viruses such as canine influenza virus or canine respiratory coronavirus [18].

Sample Selection and the Challenges of Latency

The success of molecular detection is heavily contingent upon appropriate sample selection, which must be guided by the clinical presentation and the suspected site of viral replication or shedding. For reproductive disease in bitches, vaginal swabs and uterine biopsies are the specimens of choice, while for neonatal infection, multiple organs including kidney, spleen, liver, and lung should be collected at necropsy to confirm systemic dissemination [3, 4, 21]. In the context of respiratory disease, nasal and oropharyngeal swabs are standard, although pleural effusion has also been shown to be a viable sample, with CHV-1 detected in six of 23 pleural effusions from dogs with respiratory distress [18]. For ocular disease, conjunctival swabs are the primary sample, and their analysis via PCR has become the definitive method for confirming CHV-1 as the etiological agent of conditions like dendritic corneal ulcers [2].

A critical biological challenge in CHV-1 diagnostics is the virus's ability to establish latent infections within sensory ganglia. After primary infection resolves, the viral genome persists in a quiescent state, with no infectious virus produced. Reactivation, triggered by stress, immunosuppression, or corticosteroids, can lead to renewed viral shedding, often subclinically [1, 5]. This latent state creates a diagnostic paradox: the presence of viral DNA in a swab sample indicates active or recent viral replication and shedding, whereas a negative PCR result does not rule out the presence of a latent, non-replicating virus. This distinction is clinically crucial. An intensive study by Ledbetter et al. [5] evaluated 10 dogs with experimentally-induced latent CHV-1 infection, collecting ocular swabs three times daily for 28 days and performing daily clinical ophthalmic examinations. Despite this rigorous sampling protocol, no evidence of subclinical ocular viral shedding was detected by PCR, and virus neutralizing antibody titers remained stable. This suggests that spontaneous, brief episodes of ocular reactivation may be exceedingly rare in the absence of a specific trigger, or that the virus truly remains transcriptionally silent in a significant proportion of latently infected animals [5]. This finding reinforces the understanding that PCR positivity is a clear indicator of active or recent virus excretion, but that PCR negativity, particularly from a single sample, does not preclude the animal from being a latent carrier. This has profound implications for interpreting molecular detection results in the context of screening breeding stock.

Serological Assays: Detection of Humoral Immune Responses

Serological assays provide an indirect measure of CHV-1 infection by detecting antibodies produced by the host in response to viral antigens. These assays are fundamental tools for evaluating population-level exposure, documenting seroprevalence, and understanding the immune status of individual animals, particularly in the context of maternal antibody transfer and vaccine response. The most widely used serological techniques for CHV-1 include the virus neutralization (VN) test, indirect immunofluorescence assay (IFA), and enzyme-linked immunosorbent assay (ELISA), often utilizing whole virus or recombinant viral proteins as antigens.

Virus Neutralization (VN) and Immunofluorescence Assays (IFA)

The virus neutralization test is considered the gold standard serological method for CHV-1 due to its high specificity, as it only detects functional antibodies capable of blocking viral infectivity [7, 10]. In a large serosurvey of 370 breeding dogs in Northwest Italy, the VN test revealed an overall seroprevalence of 50.3%, with more than 40% of seropositive animals exhibiting high antibody titers. Importantly, seropositivity was significantly lower in prepubertal bitches and animals younger than 1.5 years, reflecting the increased likelihood of exposure as animals age and accumulate sexual contacts [7]. This study also highlighted the dynamic nature of antibody titers; while high titers can indicate recent infection or reactivation, they can also wane over time. Similar findings have been reported in Norway, where an immunoperoxidase monolayer assay (IPMA) detected an 85.5% seroprevalence in a population of 193 breeding bitches, with season, previous whelping, and participation in shows explaining 67-78% of the variation in antibody titer [11].

The indirect immunofluorescence assay (IFA) is another commonly employed technique, particularly in diagnostic and research settings. IFA utilizes whole virus-infected cells fixed on a slide, allowing for the detection of antibodies that bind to viral antigens. A seminal serological study in Iran, using IFA, reported a 20.7% seroprevalence among 82 dogs in Kerman, establishing the endemic nature of CHV-1 in that region [14]. The IFA is valued for its relative simplicity and ability to provide semi-quantitative titer results. However, its reliance on subjective interpretation of fluorescence patterns can introduce inter-operator variability, and the production of infected cell substrates requires appropriate biosafety containment.

Recombinant Protein-Based Serology: Enhancing Specificity and Standardization

A significant advancement in CHV-1 serology involves the use of recombinant viral proteins as antigens, which can circumvent the need for whole-virus propagation and enhance assay standardization and specificity. Glycoprotein D (gD), an essential envelope protein involved in viral attachment and entry, has been identified as a promising target. Vaňková et al. [12] expressed a fragment of the CHV-1 gD gene in Escherichia coli and used the purified recombinant protein in an immunoblot assay. When compared against the indirect immunofluorescence assay on a panel of 100 canine sera, the gD-based immunoblot demonstrated a sensitivity of 89.2% and a specificity of 93.0%, with a Kappa value of 0.8, indicating substantial agreement between the two methods [12]. This approach offers several advantages: the antigen can be produced recombinantly, ensuring consistency between assays and batches; it eliminates the need to culture live virus, improving biosafety; and it allows for the rational design of antigens that may differentiate between infected and vaccinated animals (DIVA), depending on the vaccine used. Despite these advances, serological assays have an inherent limitation: they cannot distinguish between antibodies generated by natural infection and those induced by vaccination, nor can they differentiate between current active infection and past exposure [7]. This is a critical constraint in endemic populations where vaccination is practiced, as a positive serological result only confirms that an animal has been exposed to the virus or vaccine antigen, not that it is actively shedding virus. Furthermore, the interpretation of a single seropositive result in a clinically normal adult dog is of limited value; paired acute and convalescent sera demonstrating a four-fold rise in antibody titer are required to document a recent, active infection.

Strategic Considerations in Diagnostic Approach Selection

The decision to employ molecular detection or serological assays must be strategically aligned with the diagnostic objectives. For the diagnosis of acute disease, particularly in neonatal puppies or in adult dogs presenting with characteristic ocular, respiratory, or reproductive signs, PCR is the test of choice. Its ability to provide a rapid, definitive answer regarding the presence of viral DNA in a clinically relevant sample directly informs treatment decisions, such as the initiation of antiviral therapy (e.g., idoxuridine or ganciclovir) and the implementation of quarantine measures [2, 8]. For epidemiological surveys designed to assess the prevalence of exposure within a population, serological assays are indispensable. They provide a measure of cumulative incidence, revealing the proportion of animals that have encountered the virus at some point in their lives, which is essential for understanding the force of infection and designing control programs [7, 11].

However, the limitations of each approach must be carefully weighed. PCR, while exquisitely sensitive, can yield false negatives if sampling is mistimed relative to the phase of viral shedding, if the sample is improperly stored or processed, or if the virus is latent and not being shed [5]. Conversely, a positive PCR result from a mucosal swab in an asymptomatic adult dog confirms shedding but does not necessarily imply current clinical disease; it may indicate a subclinical reactivation event. Serological testing, on the other hand, reveals only a history of exposure. A seronegative result in a pregnant bitch, for instance, is a highly informative finding that identifies an animal at extreme risk of severe reproductive consequences if she contracts the virus during gestation, as she lacks protective maternal antibodies [7]. In this scenario, serology is a powerful risk-assessment tool. The challenge of diagnosing latent carriers remains the most significant hurdle in CHV-1 control. While PCR can detect reactivation events, there is currently no routine diagnostic method that can definitively identify a latently infected dog during the quiescent phase of its infection. Future diagnostic strategies may need to integrate molecular detection with immunological markers of T-cell responses or transcriptomic signatures of latency to fully characterize the infection status of a dog, particularly for the purposes of managing valuable breeding stock. The strategic integration of both molecular and serological tools, applied with a clear understanding of their respective strengths, weaknesses, and biological contexts, remains the cornerstone of effective CHV-1 diagnosis and disease management.

Therapeutic Interventions and Prophylactic Strategies for Canine Herpesvirus 1

The management of Canine Herpesvirus 1 (CHV-1) infection presents a formidable challenge to veterinary practitioners, owing to the virus’s capacity for lifelong latency, its tropism for both mucosal and neural tissues, and its ability to cause clinical syndromes ranging from mild ocular disease to fatal neonatal sepsis. A comprehensive therapeutic and prophylactic framework must therefore address acute clinical episodes, mitigate the risk of recrudescence, and reduce transmission within susceptible populations. This section critically examines the current armamentarium of antiviral agents, immunological interventions, and management strategies, with a particular focus on their mechanistic underpinnings and evidence base derived from experimental and clinical studies.

Pharmacological Interventions for Acute Ocular and Systemic Infection

Antiviral chemotherapy remains the cornerstone of therapeutic intervention for active CHV-1 infection, particularly for ocular manifestations. The clinical presentation of dendritic corneal ulcers, often accompanied by conjunctivitis and, as recently documented, quantitative tear deficiency and corneal hypoesthesia [2], necessitates prompt antiviral deployment to prevent corneal stromal involvement and reduce viral shedding. The nucleoside analogue idoxuridine, formulated as a 0.1% ophthalmic solution, has been demonstrated to effectuate resolution of dendritic ulcers, improve corneal sensitivity, and augment tear production in naturally infected dogs. Quantitative polymerase chain reaction (qPCR) analysis of conjunctival swabs from a treated French Bulldog revealed a marked reduction in viral DNA load post-therapy, with no recurrence observed over a 58-day follow-up period [2]. Idoxuridine acts by mimicking thymidine and incorporating into viral DNA, thereby inhibiting viral DNA polymerase and terminating chain elongation. While effective, its application requires frequent administration and may be associated with epithelial toxicity upon prolonged use.

A more robust evidence base supports the use of ganciclovir, a second-generation nucleoside analogue with superior selectivity for viral thymidine kinase. In a rigorous experimental study employing specific pathogen-free Beagles with experimentally induced ocular CHV-1 infection, topical administration of 0.15% ganciclovir ophthalmic gel five times daily for seven days, followed by three times daily for an additional seven days, yielded significant therapeutic benefits [8]. The ganciclovir-treated group exhibited significantly lower mean ocular disease and inflammation scores compared to controls receiving artificial tears. Crucially, the mean duration of viral shedding, as determined by qPCR of conjunctival swabs, was dramatically reduced from 6.2 days in the control group to a mere 0.4 days in the ganciclovir group [8]. The in vitro half-maximal effective concentration (EC50) of ganciclovir for CHV-1 was determined to be 37.7 μM, with no cytotoxic effects observed at concentrations up to 500 μM [8]. This favorable therapeutic index, coupled with the gel formulation’s prolonged ocular residence time, positions ganciclovir as the agent of choice for primary ocular herpesvirus infections. It is imperative to recognize that while these antiviral agents are effective against replicating virus, they do not eliminate latent viral reservoirs within trigeminal ganglia or other sites of latency, thus necessitating a comprehensive management approach that includes stress reduction and immunomodulation.

For systemic infection, particularly the hemorrhagic disease of neonates, therapeutic options are severely limited. Systemic antiviral therapy with acyclovir or valacyclovir has been attempted, but oral bioavailability is poor in dogs, and the drugs are nephrotoxic at high doses. The profound viremia and multisystemic organ failure characteristic of neonatal CHV-1 infection often preclude successful intervention by the time clinical signs are apparent [1, 3]. Consequently, the emphasis shifts decisively toward prophylaxis and early supportive care. Prophylactic topical antimicrobial therapy is recommended to prevent secondary bacterial keratitis in cases of corneal ulceration [1], although hyperthermic therapy, elevating environmental temperature for affected puppies, has failed to modify disease progression [1], a finding that underscores the primary role of viral replication rather than hypothermia in neonatal pathogenesis.

Addressing Viral Latency and Reactivation: Immunomodulation and Stress Management

The establishment of latent infection is the defining biological feature of all alphaherpesviruses, and CHV-1 is no exception. Following primary infection, which may be subclinical, the virus persists in a quiescent state within sensory neurons and, as demonstrated for closely related alphaherpesviruses, tonsillar and nasopharyngeal lymphoid tissues [26]. Reactivation from latency is precipitated by immunosuppression, physiological or environmental stress, and the administration of corticosteroids. Indeed, in a murine model of human alphaherpesvirus 1 (HSV-1) latency, explant culture of nasal-associated lymphoid tissue (NALT) with dexamethasone consistently triggered viral gene expression and production of infectious virus [26], a mechanism that is highly conserved among the Varicellovirus genus.

This stress-induced reactivation has profound clinical implications for the management of CHV-1 in breeding kennels. The high population densities, commingling of dogs at shows, and reproductive stress inherent in breeding programs create a permissive environment for viral recrudescence [4, 7, 11]. Krogenæs et al. (2014) demonstrated that season, previous whelping, and participation in competitions or shows explained 67–78% of the variation in antibody titers among Norwegian breeding bitches [11], suggesting that these factors drive repeated antigenic stimulation through reactivation events. Therapeutically, this mandates a strategy of rigorous stress mitigation: minimizing overcrowding, ensuring adequate nutrition, avoiding concurrent immunosuppressive therapy (particularly corticosteroids) during periods of risk, and implementing quarantine protocols for newly introduced animals. No pharmacological agent currently approved for veterinary use can eradicate latent CHV-1; therefore, management of the host environment is the single most effective prophylactic measure against recrudescent disease.

Vaccination: Current Status, Limitations, and Strategic Applications

Prophylactic immunization against CHV-1 has been available in several European countries, where an inactivated, adjuvanted vaccine is licensed for use in pregnant bitches to prevent neonatal disease. The vaccine is administered to the bitch during late gestation (typically the third and fifth weeks after mating), stimulating the production of maternally derived antibodies that are passively transferred to puppies via colostrum. This strategy is predicated on the well-established finding that maternal seropositivity correlates strongly with neonatal protection against fatal hemorrhagic disease [7, 11]. However, the vaccine is not core and is unavailable in many countries, including Iran, the United States, and large parts of Asia [4]. In a survey of breeding kennels in Northwest Italy, only 8.4% of dogs had been vaccinated, despite an overall seroprevalence of 50.3%, and seropositivity was predominantly attributable to natural infection rather than vaccination [7].

The limitations of the current vaccine are significant. It does not prevent infection, latency establishment, or reactivation; its efficacy is limited to the prevention of severe neonatal disease in puppies born to vaccinated dams. Furthermore, the vaccine’s capacity to induce a robust and durable neutralizing antibody response is variable. The virus itself is considered poorly immunogenic, and neutralizing antibodies are detectable for only a short time following natural exposure [10]. Consequently, the vaccine has not been widely adopted, and many breeders rely on natural immunity following enzootic circulation within their kennels. This approach, however, is fraught with risk, as seronegative pregnant bitches introduced into a kennel with active viral shedding are at extreme risk of aborting or delivering infected puppies [7].

Given these constraints, a rational vaccination strategy must be tailored to the specific epidemiological context of the kennel. Serological screening of all breeding animals to identify seronegative individuals, followed by targeted vaccination of these animals prior to breeding, represents a logical approach. However, such screening is not routinely performed, and the development of a more immunogenic, modified-live or recombinant vaccine remains a critical unmet need. The expression of recombinant glycoprotein D of CHV-1 in bacterial systems has shown promise as a serological diagnostic reagent [12], and similar recombinant platforms could be leveraged for next-generation subunit vaccine development.

Epidemiological Control in Breeding Kennels and Farms

Beyond individual animal treatment and vaccination, population-level prophylactic strategies are essential for controlling CHV-1 in high-density environments. The virus is transmitted through direct contact with infected oral, nasal, vaginal, or ocular secretions, and venereal transmission is well-documented [1, 4, 28]. The prevalence of CHV-1 in breeding kennels is alarmingly high; Rezaei et al. (2023) detected viral DNA in 33.3% of vaginal swabs from bitches in Iranian kennels and farms, with farm dogs exhibiting a significantly higher prevalence (43.7%) compared to kennel dogs (29.7%) [4]. The ease of transmission in these environments is compounded by the virus’s ability to spread through fomites and its relative stability in cool, moist environments.

Biosecurity measures must therefore include:

• Segregation of seropositive and seronegative animals: Identifying seronegative pregnant bitches and isolating them from potentially shedding conspecifics is critical during the last two weeks of gestation and the first three weeks postpartum.
• Hygiene protocols: Disinfection of kennels, feeding bowls, and hands between handling of different litters. CHV-1 is susceptible to most common disinfectants, including bleach (sodium hypochlorite) and quaternary ammonium compounds.
• Quarantine for new arrivals: A minimum 21-day quarantine period for any dog entering the breeding facility, with serological testing for CHV-1 antibody status.
• Cessation of breeding during outbreaks: Should an abortion storm or neonatal death cluster occur, all breeding activities should be suspended until the epidemiological situation is clarified and active shedding has resolved.

The molecular detection of CHV-1 in reproductive specimens from dogs with a history of pyometra, metritis, stillbirths, and vaginitis [28] underscores the virus’s role in a spectrum of reproductive pathologies. Thus, any investigation of infertility or pregnancy loss should include qPCR analysis of vaginal swabs, placental tissues, or fetal organs to rule out CHV-1 as an etiological agent. The availability of sensitive, quantitative real-time PCR assays targeting conserved genes such as glycoprotein B or thymidine kinase [21, 23, 27] enables both ante-mortem diagnosis and post-mortem confirmation, facilitating timely implementation of control measures.

Conclusion of Therapeutic and Prophylactic Considerations

In summary, the management of CHV-1 requires a triad of approaches: (1) prompt antiviral therapy with ganciclovir or idoxuridine for acute ocular disease, (2) meticulous stress management and avoidance of corticosteroid use to prevent reactivation, and (3) implementation of rigorous biosecurity and selective vaccination protocols in breeding establishments. The absence of a sterilizing vaccine or an effective antiviral regimen capable of clearing latent infection means that control hinges on epidemiological awareness and proactive management. Future research should prioritize the development of vaccines that elicit robust mucosal immunity and the exploration of novel antiviral targets, such as viral helicase-primase inhibitors, which have shown success against human alphaherpesviruses. Until such innovations reach clinical practice, the veterinary clinician must rely on a judicious combination of pharmacotherapy and environmental stewardship to mitigate the impact of this pervasive and economically significant pathogen.

Environmental and Host Factors Influencing Canine Herpesvirus 1 Reactivation and Spread

The epidemiology of Canine Herpesvirus 1 (CHV-1) is a complex interplay between the virus’s capacity for lifelong latency, specific environmental conditions that facilitate transmission, and a spectrum of host-related factors that govern both susceptibility to primary infection and the likelihood of viral reactivation. Understanding these determinants is critical for designing effective management strategies, particularly in high-density populations such as breeding kennels and research facilities, where the consequences of an outbreak can be devastating. This section provides an exhaustive analysis of the environmental and host factors that modulate CHV-1 reactivation and spread, drawing upon molecular, serological, and epidemiological evidence.

The Central Role of Latency and Immunosuppression in Reactivation

A defining feature of all alphaherpesviruses, including CHV-1, is their ability to establish a latent infection within the host following resolution of the primary disease. The virus persists in a transcriptionally quiescent state, primarily within sensory neurons of the trigeminal ganglia and, as demonstrated for related alphaherpesviruses, potentially within lymphoid tissues such as the tonsils and nasopharyngeal-associated lymphoid tissue (NALT) [26]. This latent reservoir is the cornerstone of CHV-1 persistence within a population, as it allows the virus to evade immune clearance for the lifetime of the host. Reactivation from latency, leading to renewed viral shedding and potential transmission, is the critical event that perpetuates the infection cycle.

The primary trigger for reactivation is immunosuppression, which can be induced by a variety of endogenous and exogenous stressors. The administration of exogenous corticosteroids, such as dexamethasone, is a well-established experimental model for inducing reactivation of alphaherpesviruses. Mechanistically, corticosteroids bind to glucocorticoid receptors, which then act as transcription factors that can directly stimulate the viral immediate-early gene promoters, thereby initiating the lytic cascade. This phenomenon has been robustly demonstrated for bovine herpesvirus 1 and, by extrapolation, is a potent trigger for CHV-1 reactivation [26]. In a clinical context, any condition that elevates endogenous cortisol levels can similarly precipitate viral recrudescence. This includes physiological stress associated with parturition, lactation, overcrowding, transportation, concurrent illness, and poor nutritional status. The stress of whelping is a particularly well-documented risk factor, as the hormonal upheaval and physical exertion can reactivate latent virus in the bitch, leading to the shedding of virus in vaginal and oronasal secretions at the time of birth, which is the primary route of infection for neonates [1, 4, 7].

Environmental Factors: Density, Hygiene, and Facility Design

The physical environment in which dogs are housed is a powerful determinant of CHV-1 transmission dynamics. The virus is relatively labile in the environment, being susceptible to desiccation, heat, and common disinfectants. However, in the presence of organic material and under favorable conditions, it can survive long enough to facilitate indirect transmission via fomites.

Population Density and Kennel Size: The single most significant environmental risk factor for CHV-1 spread is high population density. Studies consistently demonstrate a higher prevalence of CHV-1 in dogs housed in breeding kennels and farms compared to privately owned pets [1, 4, 9]. For instance, a study in Iran found a prevalence of 43.7% in farm dogs compared to 29.7% in kennel dogs, and the difference was statistically significant [4, 9]. The close confinement of animals facilitates direct contact transmission via oronasal or venereal routes. Furthermore, high density increases the frequency of aerosol or droplet transmission over short distances, particularly in poorly ventilated spaces. The size of the breeding facility and the number of dogs housed together directly correlate with the force of infection, as the probability of a susceptible individual encountering a shedding animal increases exponentially with population density [1]. In such environments, the virus becomes enzootic, with a constant cycle of reactivation and transmission maintaining a high seroprevalence. A study in Northwest Italy found that in 30.3% of kennels, no seropositive dogs were identified, but in positive kennels, seroprevalence ranged from 7.1% to 100%, illustrating the stark contrast between facilities with and without active viral circulation [7].

Hygiene and Management Practices: Poor hygiene is a major amplifier of transmission. CHV-1 is shed in high titers in vaginal, ocular, nasal, and oropharyngeal secretions, as well as in urine and feces from infected neonates [1, 18]. Contaminated bedding, food bowls, water sources, and the hands or clothing of handlers can serve as fomites. Facilities with suboptimal cleaning and disinfection protocols allow the virus to persist and spread rapidly. The presence of organic matter (e.g., feces, saliva, uterine discharge) can protect the virus from desiccation and inactivate disinfectants, making thorough cleaning a prerequisite for effective disinfection. The lack of quarantine protocols for new arrivals is another critical management failure. Introducing a latently infected dog into a naive population can trigger an outbreak, especially if the newcomer is stressed by transport and a novel environment, leading to reactivation and shedding [10].

Ventilation and Microclimate: While CHV-1 is not considered a highly airborne virus over long distances, its transmission is facilitated by poor air quality and inadequate ventilation. Stagnant air in enclosed kennels increases the concentration of viral particles in aerosols generated by sneezing or coughing. This is particularly relevant for the canine infectious respiratory disease complex (CIRDC), where CHV-1 frequently acts as a co-pathogen [18, 20, 23, 27, 30]. The virus’s preference for infecting polarized epithelial cells from the basolateral surface [15] suggests that disruption of the respiratory epithelium by other pathogens or environmental irritants (e.g., ammonia from urine) may facilitate viral entry and exacerbate disease.

Host Factors: Age, Immunity, and Reproductive Status

Host-related factors profoundly influence susceptibility to primary infection, the severity of clinical disease, and the likelihood of reactivation.

Age as a Dichotomous Factor: Age exerts a bimodal effect on CHV-1 pathogenesis. In neonates (puppies under 3 weeks of age), the infection is almost invariably fatal due to their inability to thermoregulate. The virus replicates optimally at temperatures below the canine core body temperature (approximately 35-37°C), which corresponds to the lower body temperature of neonates [1]. This results in a fulminant, systemic hemorrhagic disease. In contrast, adult dogs typically experience mild or subclinical infections, with disease manifesting primarily as upper respiratory signs, ocular lesions (e.g., dendritic ulcers, conjunctivitis), or reproductive disorders [1, 2, 18]. However, age also influences seroprevalence. Studies consistently show that seropositivity increases with age, reflecting cumulative exposure over time. For example, a study in Iran found that infection rates were significantly higher in dogs older than 3 years compared to younger groups [14]. Similarly, a study in Norway found that the number of seropositive animals was significantly lower in prepubertal bitches and animals younger than 1.5 years [11]. This indicates that while adults are more resistant to severe disease, they are the primary reservoir for the virus.

Immune Status and Vaccination: The host immune response is the primary defense against both primary infection and reactivation. Humoral immunity, particularly virus-neutralizing antibodies, plays a crucial role in limiting viral spread and preventing reinfection. However, CHV-1 is considered poorly immunogenic, and antibody titers can wane over time [10]. A high seroprevalence in a population indicates widespread exposure and the development of some level of herd immunity. In a study of breeding dogs in Italy, 50.3% were seropositive, with over 40% showing high titers, suggesting recent or repeated exposure [7]. However, seropositivity does not guarantee protection against reactivation; latently infected animals can still shed virus despite having circulating antibodies. Vaccination is a critical tool for boosting immunity, particularly in breeding bitches. The goal of vaccination is to maintain high antibody titers during pregnancy, thereby providing passive immunity to puppies via colostrum. However, vaccine uptake is often low. In the Italian study, only 8.4% of dogs had been vaccinated, and in many regions, including Iran, no licensed vaccine is available, making management strategies the only line of defense [4, 7]. The presence of concurrent infections, such as canine parvovirus, distemper, or respiratory bacteria, can further immunosuppress the host, increasing the risk of CHV-1 reactivation and severe disease [18, 32, 33].

Reproductive Status and Sex: The reproductive tract is a major site of CHV-1 latency and reactivation. In bitches, the hormonal changes associated with estrus and pregnancy are potent reactivation triggers. Viral shedding in vaginal secretions is most commonly detected during proestrus, estrus, and immediately postpartum [4, 28, 29]. This is the primary mechanism for venereal transmission to the male and for infecting newborn puppies during passage through the birth canal. A study in Iran detected CHV-1 DNA in 15% of reproductive samples, with a higher prevalence in uterine biopsies (20%) than in vaginal swabs (10%), highlighting the deep tissue involvement [28, 29]. The virus is also a significant cause of reproductive disorders, including abortion, stillbirth, and infertility [1, 4, 28]. While sex itself does not appear to be a significant risk factor for seroprevalence [7, 14], the reproductive cycle of the female creates specific windows of high transmission risk. In males, the virus can be shed in semen and is associated with lesions on the penis and prepuce, contributing to venereal spread [17].

Geographic and Climatic Influences

CHV-1 has a global distribution, but its prevalence varies significantly by region, influenced by management practices, dog population density, and climate. Seroprevalence rates reported in the literature range widely, from 20.7% in Iran to 85.5% in Norway [11, 14]. These differences are likely due to a combination of factors, including the type of population sampled (e.g., pet dogs vs. kennel dogs), the diagnostic methods used, and true epidemiological differences. A study in Norway found that season, previous birth, and participation in competitions/shows explained 67-78% of the variation in antibody titer, suggesting that environmental and behavioral factors are more important than broad climatic zones [11]. While the virus is thermolabile, and environmental temperature increase for affected puppies fails to modify disease progression [1], the virus can survive longer in cooler, humid environments, which may facilitate indirect transmission in temperate climates. The first molecular detection of CHV-1 in the Eastern Brazilian Amazon [6] and in Japan [2] confirms its ability to circulate in diverse tropical and subtropical environments, indicating that host density and management are more critical limiting factors than climate alone. The World Organisation for Animal Health (WOAH) recognizes CHV-1 as a significant pathogen of canids, and its global distribution underscores the need for international surveillance and standardized control measures.

References

[1] Soleimani S, Ghorani M, Javaheri AMN, Shirafkan M, Bakhtiari H. Prevalence and Clinical Impacts of Canine Herpesvirus‐1 (CHV‐1) in Dogs: A Review of Reproductive Effects and Ocular Lesions. Veterinary Medicine and Science. 2025. DOI: https://doi.org/10.1002/vms3.70682

[2] Usami K, Komatsu H, Akasaka M, Morita M, Kumashiro K, Inagaki M, et al.. Canine Herpesvirus-1 Ocular Infection in Japan: A Case Report.. Veterinary Ophthalmology. 2025. DOI: https://doi.org/10.1111/vop.70072

[3] Rocchigiani A, Bertoldi L, Coradduzza E, Lostia G, Pintus D, Scivoli R, et al.. Whole-Genome Sequencing of Two Canine Herpesvirus 1 (CaHV-1) Isolates and Clinicopathological Outcomes of Infection in French Bulldog Puppies. Viruses. 2024. DOI: https://doi.org/10.3390/v16020209

[4] Rezaei M, Jajarmi M, Kamani S, Khalili M, Babaei H. Prevalence of canine herpesvirus 1 and associated risk factors among bitches in Iranian breeding kennels and farms. Veterinary Medicine and Science. 2023. DOI: https://doi.org/10.1002/vms3.1246

[5] Ledbetter E, Spertus CB, Diel D, Dubovi E. Intensive ocular sampling for the detection of subclinical canine herpesvirus-1 shedding in dogs with experimentally-induced latent infection.. Veterinary Microbiology. 2021. DOI: https://doi.org/10.1016/j.vetmic.2021.109001

[6] Castro MDS, David MBM, Gonçalves E, Siqueira A, Virgulino RR, Aguiar D. First molecular detection of canine herpesvirus 1 (CaHV-1) in the Eastern Brazilian Amazon. Journal of Veterinary Sciences. 2021. DOI: https://doi.org/10.4142/jvs.21202

[7] Rota A, Dogliero A, Biosa T, Messina M, Pregel P, Masoero L. Seroprevalence of Canine Herpesvirus-1 in Breeding Dogs with or Without Vaccination in Northwest Italy. Animals. 2020. DOI: https://doi.org/10.3390/ani10071116

[8] Ledbetter E, Nicklin A, Spertus CB, Pennington M, Walle GRVd, Mohammed H. Evaluation of topical ophthalmic ganciclovir gel for the treatment of dogs with experimentally induced ocular canine herpesvirus-1 infection.. American Journal of Veterinary Research. 2018. DOI: https://doi.org/10.2460/ajvr.79.7.762

[9] Rezaei M, Jajarmi M, Kamani S, Khalili M, Babaei H. Detection of Canine herpesvirus 1 in the breeding kennel and farm dogs by Real-time PCR. . 2020. DOI: https://doi.org/10.21203/rs.3.rs-16008/v1

[10] Bottinelli M, Rampacci E, Stefanetti V, Marenzoni ML, Malmlov A, Coletti M, et al.. Serological and biomolecular survey on canine herpesvirus-1 infection in a dog breeding kennel. Journal of Veterinary Medical Science. 2016. DOI: https://doi.org/10.1292/jvms.15-0543

[11] Krogenæs A, Rootwelt V, Larsen S, Renström L, Farstad W, Lund A. A serological study of canine herpesvirus-1 infection in a population of breeding bitches in Norway. Acta Veterinaria Scandinavica. 2014. DOI: https://doi.org/10.1186/1751-0147-56-19

[12] Vaňková M, Molínková D, Celer V. The expression and serological reactivity of recombinant canine herpesvirus 1 glycoprotein D. Acta Veterinaria Brno. 2016. DOI: https://doi.org/10.2754/AVB201685020113

[13] Nakamichi K, Ôhara K, Matsumoto Y, Otsuka H. Attachment and penetration of canine herpesvirus 1 in non-permissive cells.. Journal of Veterinary Medical Science. 2000. DOI: https://doi.org/10.1292/JVMS.62.965

[14] Babaei H, Akhtardanesh B, Ghanbarpour R, Namjoo A. Serological evidence of canine herpesvirus-1 in dogs of Kerman city, south-east of Iran.. Transboundary and Emerging Diseases. 2010. DOI: https://doi.org/10.1111/j.1865-1682.2010.01155.x

[15] Eisa M, Micky S, Pearson A. Canid herpesvirus 1 Preferentially Infects Polarized Madin-Darby Canine Kidney Cells from the Basolateral Surface. Viruses. 2022. DOI: https://doi.org/10.3390/v14061291

[16] Eisa M, Loucif H, Grevenynghe J, Pearson A. Entry of the Varicellovirus Canid herpesvirus 1 into Madin–Darby canine kidney epithelial cells is pH‐independent and occurs via a macropinocytosis‐like mechanism but without increase in fluid uptake. Cellular Microbiology. 2021. DOI: https://doi.org/10.1111/cmi.13398

[17] Domrazek K, Jurka P. Prevalence of Chlamydophila spp. and Canid herpesvirus-1 in Polish dogs. Veterinary World. 2024. DOI: https://doi.org/10.14202/vetworld.2024.226-232

[18] Piewbang C, Rungsipipat A, Poovorawan Y, Techangamsuwan S. Viral molecular and pathological investigations of Canid herpesvirus 1 infection associated respiratory disease and acute death in dogs. Acta Veterinaria. 2017. DOI: https://doi.org/10.1515/acve-2017-0002

[19] Küçük A, Yıldırım Y. Felide Herpesvirus – 1 Enfeksiyonu. Etlik Veteriner Mikrobiyoloji Dergisi. 2018. DOI: https://doi.org/10.35864/EVMD.513036

[20] Thieulent CJ, Carossino M, Peak L, Strother K, Wolfson W, Balasuriya UBR. Development and Validation of a Panel of One-Step Four-Plex qPCR/RT-qPCR Assays for Simultaneous Detection of SARS-CoV-2 and Other Pathogens Associated with Canine Infectious Respiratory Disease Complex. Viruses. 2023. DOI: https://doi.org/10.3390/v15091881

[21] Decaro N, Amorisco F, Desario C, Lorusso E, Camero M, Bellacicco A, et al.. Development and validation of a real-time PCR assay for specific and sensitive detection of canid herpesvirus 1. Journal of Virological Methods. 2010. DOI: https://doi.org/10.1016/j.jviromet.2010.07.021

[22] Dong J, Tsui W, Leng X, Fu J, Lohman M, Anderson J, et al.. Validation of a real-time PCR panel for detection and quantification of nine pathogens commonly associated with canine infectious respiratory disease. MethodsX. 2023. DOI: https://doi.org/10.1016/j.mex.2023.102476

[23] Dong J, Tsui W, Leng X, Fu J, Lohman M, Anderson J, et al.. Development of a three-panel multiplex real-time PCR assay for simultaneous detection of nine canine respiratory pathogens.. Journal of Microbiological Methods. 2022. DOI: https://doi.org/10.1016/j.mimet.2022.106528

[24] More G, Cave N, Biggs P, Acke E, Dunowska M. A molecular survey of canine respiratory viruses in New Zealand. New Zealand Veterinary Journal. 2021. DOI: https://doi.org/10.1080/00480169.2021.1915211

[25] C SLN. Determination of Permissive Cellular Lines to the Canine Herpes Virus, by Visualization of the Cytopathic Effect. Biomedical Journal of Scientific & Technical Research. 2018. DOI: https://doi.org/10.26717/bjstr.2018.10.002028

[26] Harrison KS, Cowan S, Jones C. Murine nasal-associated lymphoid tissue (NALT) harbors human alphaherpesvirus 1 (HSV-1) DNA during latency, and dexamethasone triggers viral replication. Journal of Virology. 2025. DOI: https://doi.org/10.1128/jvi.02251-24

[27] Li Y, Wu J, Wang C, Jia Z, Yang Z, Lin W, et al.. Development of one-step multiplex real-time PCR for the detection of CHV-1, CAdV-2, and CDV. Frontiers in Veterinary Science. 2025. DOI: https://doi.org/10.3389/fvets.2025.1583769

[28] Rezaei M, Jajarmi M, Alizadeh R, Khalili M, Babaei H. First molecular study of Canine herpesvirus-1 in reproductive specimens of adult dogs in southeast of Iran.. Comparative Immunology, Microbiology & Infectious Diseases. 2020. DOI: https://doi.org/10.1016/j.cimid.2020.101487

[29] Rezaei M, Jajarmi M, Alizadeh R, Khalili M, Babaei H. The first molecular detection of Canine herpesvirus-1 in reproductive specimens of adult dogs in Iran. . 2019. DOI: https://doi.org/10.21203/rs.2.16695/v1

[30] Matsuu A, Yabuki M, Aoki E, Iwahana M. Molecular detection of canine respiratory pathogens between 2017 and 2018 in Japan. Journal of Veterinary Medical Science. 2020. DOI: https://doi.org/10.1292/jvms.20-0017

[31] Piewbang C. Development of multiplex RT-PCR and metagenomic analyses of canine infectious respiratory disease complex associated viruses in dogs. . None. DOI: https://doi.org/10.58837/chula.the.2017.548

[32] Marenzoni ML, Chierchia F, Sylla L, Rossi E, Beccaglia M, Marini D, et al.. Detection of Mycoplasma DNA Using Conventional Polymerase Chain Reaction in Canine Abortion, Stillbirth, and Neonatal Mortality Cases in Central Italy. Pathogens. 2024. DOI: https://doi.org/10.3390/pathogens13110970

[33] Amoroso M, Concilio DD, D'Alessio N, Veneziano V, Galiero G, Fusco G. Canine parvovirus and pseudorabies virus coinfection as a cause of death in a wolf (Canis lupus) from southern Italy. Veterinary Medicine and Science. 2020. DOI: https://doi.org/10.1002/vms3.270